These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 15082132)

  • 1. Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study.
    Schulte-Mattler WJ; Krack P;
    Pain; 2004 May; 109(1-2):110-4. PubMed ID: 15082132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Botulinum toxin in tension-type headache.
    Relja M; Telarović S
    J Neurol; 2004 Feb; 251 Suppl 1():I12-4. PubMed ID: 14991337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum toxin a in the treatment of chronic tension-type headache with cervical myofascial trigger points: a randomized, double-blind, placebo-controlled pilot study.
    Harden RN; Cottrill J; Gagnon CM; Smitherman TA; Weinland SR; Tann B; Joseph P; Lee TS; Houle TT
    Headache; 2009 May; 49(5):732-43. PubMed ID: 19178577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
    Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM;
    Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
    Dodick DW; Mauskop A; Elkind AH; DeGryse R; Brin MF; Silberstein SD;
    Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache.
    Mathew NT; Kailasam J; Meadors L
    Headache; 2008 Feb; 48(2):194-200. PubMed ID: 17868356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of chronic tension-type headache with botulinum toxin: a double-blind, placebo-controlled clinical trial.
    Padberg M; de Bruijn SF; de Haan RJ; Tavy DL
    Cephalalgia; 2004 Aug; 24(8):675-80. PubMed ID: 15265057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of tension-type headache with botulinum toxin: a pilot study.
    Schulte-Mattler WJ; Wieser T; Zierz S
    Eur J Med Res; 1999 May; 4(5):183-6. PubMed ID: 10336407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials.
    Shuhendler AJ; Lee S; Siu M; Ondovcik S; Lam K; Alabdullatif A; Zhang X; Machado M; Einarson TR
    Pharmacotherapy; 2009 Jul; 29(7):784-91. PubMed ID: 19558252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
    Wissel J; Entner T
    Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study.
    Truong D; Duane DD; Jankovic J; Singer C; Seeberger LC; Comella CL; Lew MF; Rodnitzky RL; Danisi FO; Sutton JP; Charles PD; Hauser RA; Sheean GL
    Mov Disord; 2005 Jul; 20(7):783-91. PubMed ID: 15736159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse.
    Freitag FG; Diamond S; Diamond M; Urban G
    Headache; 2008 Feb; 48(2):201-9. PubMed ID: 18042229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum toxin in migraine prophylaxis.
    Göbel H
    J Neurol; 2004 Feb; 251 Suppl 1():I8-11. PubMed ID: 14991336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study.
    Silberstein SD; Göbel H; Jensen R; Elkind AH; Degryse R; Walcott JM; Turkel C
    Cephalalgia; 2006 Jul; 26(7):790-800. PubMed ID: 16776693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of tension-type headache with botox: a review of the literature.
    Rozen D; Sharma J
    Mt Sinai J Med; 2006 Jan; 73(1):493-8. PubMed ID: 16470328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective randomized controlled study of the role of botulinum toxin in whiplash-associated disorder.
    Carroll A; Barnes M; Comiskey C
    Clin Rehabil; 2008 Jun; 22(6):513-9. PubMed ID: 18511531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study.
    Göbel H; Heinze A; Reichel G; Hefter H; Benecke R;
    Pain; 2006 Nov; 125(1-2):82-8. PubMed ID: 16750294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration of migraine is a predictor for response to botulinum toxin type A.
    Eross EJ; Gladstone JP; Lewis S; Rogers R; Dodick DW
    Headache; 2005 Apr; 45(4):308-14. PubMed ID: 15836566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pericranial injection of botulinum toxin type A (Dysport) for tension-type headache - a multicentre, double-blind, randomized, placebo-controlled study.
    Straube A; Empl M; Ceballos-Baumann A; Tölle T; Stefenelli U; Pfaffenrath V;
    Eur J Neurol; 2008 Mar; 15(3):205-13. PubMed ID: 18290842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.